Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421682 | 0.89 | HTR1A (0.46) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL13052119 | 0.77 | ALDH1A1 (0.35) | HPGDHSD17B10ALDH1A1USP2KDM4E | |
| SCHEMBL30168645 | 0.76 | MCL1 (0.51) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL17520237 | 0.74 | HSD17B10 (0.57) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL9811408 | 0.74 | MCL1 (0.60) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL3232440 | 0.72 | KDM4E (0.39) | HPGDHSD17B10ALDH1A1USP2KDM4E | |
| SCHEMBL12000241 | 0.72 | MCL1 (0.55) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL15181677 | 0.72 | MCL1 (0.55) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL31192194 | 0.71 | MCL1 (0.53) | HPGDMCL1HSD17B10ALDH1A1USP2 | |
| SCHEMBL6346613 | 0.71 | MCL1 (0.57) | HPGDMCL1HSD17B10ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2020190604-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3534885-A2 | FARNESYLTRANSFERASE INHIBITORS FOR USE IN METHODS OF TREATING CANCER | Kura Oncology, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3239147-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2019-08-28 | — | — | EP | disclosed |
| WO-2019113269-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-10208034-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-3277842-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170349583-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349583-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3239147-A1 | QUINOLINE DERIVATIVE | Ono Pharmaceutical Co., Ltd. (JP) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017031101-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2016104617-A1 | QUINOLINE DERIVATIVE | 小野薬品工業株式会社 | 2016-06-30 | — | — | WO | disclosed |
| EP-0017012-B1 | DYES AND PROCESS FOR THE GENERATION OF TINTS BASED ON OPTIONALLY SUBSTITUTED 2-AMINO-5-IMINOPYRROLENINES | BAYER AG (DE) | 1983-10-05 | — | — | EP | disclosed |
| EP-0017012-A2 | Dyes and process for the generation of tints based on optionally substituted 2-amino-5-iminopyrrolenines | BAYER AG (DE) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | HPGD 728/4885MCL1 1521/4885HSD17B10 1456/4885 |
| US-20170349583-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ABL1 | HPGD 4237/4885MCL1 8/4885HSD17B10 4758/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | HPGD 1211/4885MCL1 702/4885HSD17B10 4028/4885 |
| US-10208034-B2 | Quinoline derivative | FLT3, AXL, ABL1 | HPGD 4237/4885MCL1 8/4885HSD17B10 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.